Survivin在鼻咽癌中的表达及意义  

Expression and Significance of Survivin in Nasopharyngeal Carcinoma

作　　者：何跃平[1] 郑家法[1] 申海荣[1] 田梦秋[1] 梁贵玲[1] 张艳[2] 

机构地区：[1]南华大学附属南华医院,湖南衡阳421002 [2]南华大学医学微生物学与免疫学教研室

出　　处：《南华大学学报（医学版）》2005年第3期357-360,共4页Journal of Nanhua University(Medical Edition)

摘　　要：目的探讨凋亡抑制因子Survivin在鼻咽癌中的表达及其临床意义。方法用逆转录聚合酶链反应(RT-PCR)和Westernblot免疫印迹法,检测2株鼻咽癌细胞株、25例鼻咽癌组织及对应的对侧鼻咽部黏膜、10例正常人的鼻咽部黏膜组织中SurvivinmRNA和蛋白的表达。结果Survivin在正常鼻咽部黏膜组织中不表达。2株鼻咽癌细胞株、80.0%的鼻咽癌组织和40.0%的对应对侧相对正常鼻咽部黏膜中均可检测到Survivin基因mRNA和蛋白的表达,SurvivinmRNA在鼻咽癌组织中的表达较对应的对侧鼻咽部黏膜组织高,其吸光度(A)比值分别为0.83±0.22和0.29±0.14,差异有显著性(P<0.01);Survivin蛋白在鼻咽癌中的表达同样高于对侧鼻咽部黏膜组织,其A值分别为33680±1466和17925±1908,差异有显著性(P<0.01)。Ⅲ+Ⅳ的鼻咽癌病人中Survivin表达强度明显高于Ⅰ+Ⅱ的鼻咽癌病人(P<0.05)。鼻咽癌组织中Survivin阳性表达与患者的年龄、性别、鼻咽癌细胞的分化程度及有无淋巴结转移无相关性(P>0.05)。结论Survivin的过度表达可能在鼻咽癌发生、发展过程中起一定作用,检测Survivin在鼻咽癌中的表达对鼻咽癌的诊断、临床分期有一定意义。Objective To study the expression and clinical significance of apoptosis inhibitor Survivin in nasopharyngeal carcinoma(NPC). Methods The expression level of Survivin mRNA and protein in two human nasopharyngeal arcinoma cell lines, biopsies of 25 NPC and opposite nasopharyngeal mucosa and 10 normal nasopharygeal epithelium were examined by RT-PCR and Western blot. Results No Survivin was detected in normal nasopharygeal epithelium. However, the expression of Survivin mRNA and protein was found in two NPC cell lines,80.0% NPC and 40.0% opposite nasopharyngeal mucosa. The expression level of Survivin mRNA and proterin was significantly higher in NPC than that in opposite nasopharyngeal mucosa( 0.83±0.22 vs 0.29±0.14; 33 680±1 466 vs 17 925±1 908,P<0.01).The degree of Survivin overexpression was even more marked in Ⅲ+Ⅳ stage NPC than in Ⅰ+Ⅱ stage NPC. Expression of survivin was unrelated with the ages and sexes of patients or the degree of cell differentiation and the lymphatic metasis of the tumor. Conclusion Survivin overexpression may play some roles in pathogenesis of NPC. Detection of Survivin will be helpful for diagnosis and clinical staging of NPC.

关 键 词：SURVIVIN 鼻咽癌 

分 类 号：R739.63[医药卫生—肿瘤] Q343.1[医药卫生—临床医学]